Ailin.health’s Post

😲 February is only halfway through but it's already been a busy and successful month for the AMIRES #Health & #Biotech Programme! 🎉 On 6th February 2024, we hosted the “Pioneering Digital Transformation in Healthcare” #workshop, which was a great success! The event brought together different projects in AMIRES Health & Biotech portfolio: PANCAIM, NetZeroAICT, RES-Q+, as well as longstanding partners as well as external speakers and guests. The insights and experiences shared by speakers covered #digitalhealth from a variety of perspectives. During the #networking reception, many ideas on ongoing #projects and future #cooperation opportunities were exchanged - we hope that we will see some of them come to life in the near future! A big thank you to all speakers and participants for the active engagement during the workshop! 😊 ➡ Read more about our key #takeaways from the workshop: https://lnkd.in/eG7xaKht 👋 Following the event, from the 7th to 8th February, we welcomed the PANCAIM partners in Prague for the project's M36 Meeting where we discussed exciting #progress in the development of #AI for #pancreaticcancer! More info on that here: https://lnkd.in/eass_jjY 🔬 Meanwhile, MedPhab Pilot Line partners have met in Leuven, Belgium, at imec site to plan last phase of the project and transitioning towards a MedPhab non-profit association led by VTT. Visit www.medphab.com to see how #MedPhab can help you accelerate #photonic medical device development! ✅Lastly, the beginning of the year is the season of project reviews, and our colleagues are presenting their activities and achievements in #projectmanagement and #dissemination to the European Commission! eCAP Project has successfully completed the EC review procedure in January, while the PANCAIM review meeting is upcoming on 16th of February. We keep our fingers crossed for helpful feedback and a positive evaluation of our work! #HealthcareHorizons #healthcareinnovation #biotechnews 

So where did the idea for Pepticom come from? After fighting potential brain cancer that gave him a new perspective on life, our Co-founder & CTO, Dr. Amit Michaeli, set out on a mission to develop life-changing treatments where no treatments exist today, Driven by a clear purpose to ensure no-one ever faced a disease without a potential treatment led him to discover a groundbreaking peptide for the very rare #orphandisease, Adult Polyglucosan Body Disease (APBD). This primarily affects a small community of Ashkenazi Jews. Leveraging the early AI technology that would become Pepticom, Amit managed to unlock a potential solution. Though its path to mainstream availability has proven challenging due to its small patient population, the technology idea led to the birth of Pepticom. Now we can explore a whole new chemical space using AI to discover not just one peptide, but potentially hundreds of new peptide treatments. These offer new hope to not only improve on existing treatments for better quality of life but we now have the technology to help find new cures where no treatments exist today! If you are interested in learning more and attending #JPM2024 next week, please join the Pepticom Ltd. team - Immanuel Lerner, Ph.D., Maayan Elias Robicsek and Sarah Benson-Konforty, MD at the J.P. Morgan JPM Health Innovation Lounge of CICC - California Israel Chamber of Commerce > https://lnkd.in/g-KmQB5Q #drugdiscovery #AI #peptides #startups

This is a common question we get asked. If you are interested in learning more and attending #JPM2024 next week, please join myself and the team - Maayan Elias Robicsek and Sarah Benson-Konforty, MD at the JPM Health Innovation Lounge of CICC - California Israel Chamber of Commerce. #drugdiscovery #AI #peptides #startups

🧬 This week's Austin Bio + Health Roundup brings exciting funding announcements, important community events, accolades, partnerships, and milestones from across the Texas Bio Triangle. 🧬 💰 Funding Humanaut Health has secured an $8.7M seed round to bring access to health optimization and longevity to the general population. It's Austin funding Austin, as Midnight Venture Partners joined the round. Don't miss my short interview with Co-founder and CEO Jim Donnelly below! Optmycare, an AI platform in healthcare & risk management, raised a $3 million in Series A funding, led by Austin's own LiveOak Ventures, to accelerate its growth and build out its technology. 🏙️ Community Mark your calendars for the Nucleate Texas Final Pitch Showcase on May 17th. Catch the final pitches from 1pm to 5pm at Highpoint 2222, and discover what's next in platform discoveries, diagnostics, and therapeutics. 🏆 Recognition BrainCheck, a brain health diagnostic and tools company, received the Care Management Innovation Award at the 8th annual MedTech Breakthrough Awards. Congratulations Kim Rodriguez and the entire team for the well-deserved recognition of your work.   🤝 M&A and Partnerships Babson Diagnostics has announced a new partnership with Cynergy Wellness LLC, to provide clinician oversight for Babson’s customer-initiated BetterWay blood tests. One more step in providing access to this novel technology. Congrats David Stein, Eric Olson and the rest of the Babson team. 🚩 Texas Bio Triangle San Antonio-based Hera Biotech has released promising interim results for their groundbreaking endometriosis treatment. The data showed 92% sensitivity, 95% specificity, and 94% overall accuracy compared to histopathology. Congrats Somer Baburek, MBA on this important step in the development of a greatly needed diagnostic. This week underscores breadth and depth of sector. Let's keep the momentum going! What’s Next? #AustinNext #LifeSciences #Healthcare #Biotechnology

Check out this week's Austin Bio + Health Roundup for all the latest news in the ecosystem!

Last week, our very own Jim Donnelly connected with Jason Scharf of Austin Next to discuss the connection between strong health outcomes and a holistic care approach. What you need to know:  - Our model is proactive and preventative  - We provide medical and wellness therapies - We support behavior change with private coaching #humanauthealth, #austinnext, #longevity, #healthspan, #betteraging, #startup, #healthcare

Stefan Mazy is the Founder and CEO of DermR Health, who are on a mission to transform skin cancer detection by replacing painful biopsies with a simple, non-invasive patch. Currently, over 1 billion biopsies are performed worldwide, however over 40% of skin biopsies are benign, and can be avoided. The DermR Patch offers a solution that is accessible to all. By combining innovative device technology with advanced diagnostics, the DermR Patch requires only a minimal cell sample, and can be performed by any genomics-enabled pathology providers to detect a spectrum of skin cancers, such as melanoma. In his Tech23 talk, Stefan highlighted how DermR’s solution addresses critical healthcare needs in remote and Indigenous communities. “The Western Australian Government's new Pilbara Challenge, [allowed us] the opportunity to go on country to smaller Indigenous communities of 200 people, gaining insights into the challenges and limitations of remote healthcare delivery.” Supported by the Department of Health (WA Health) and the Pilbara Aboriginal Health Alliance - PAHA, DermR accelerated its development timeline by over 2.5 years, demonstrating the impact of transforming regional healthcare. Watch Stefan’s full insights on the transformative power of deep tech in the dermatology sector: https://lnkd.in/gq4aqWdn And stay up-to-date with our Tech23 here: https://lnkd.in/gAxNCxz2 #skincancer #innovatioontech #deeptech #innovation #pilbarachallenge #indigenoushealth #healthcareaccess  #CxT23 #tech #deeptech #techfestival #australianstartups

I am honored to be speaking at LSX World Congress USA on the unifying topic of #healthequity, alongside Arianne Kidder of Seae Ventures, Dorosella Green, MS-PREP of Takeda and Willie T. Reaves Jr. of Cellino. As healthcare systems around the world strive for #fairness and #equity, #DTx are playing a more pivotal role every day in addressing #disparities in #access, #treatment, and #outcomes. I'm delighted to bring a perspective to the panel on how #digitaltherapeutics can contribute to a more #equitable healthcare landscape by: 1️⃣ Increased Accessibility Breaking Down Capacity, #Training, Geographic, Transportation Infrastructure, #Income and Time-of-Day Barriers 2️⃣ #Cost and Quality Enhancements driven by Affordable #DTx Solutions that complement #HCPs, Care Teams and #Medicines to Achieve Better Outcomes 3️⃣ Personalized Treatment for the Most #Diverse Populations based in #Cultural Competence and amplified by #AdaptiveLearning through data analytics, #ML and #AI 4️⃣ Enhanced #Engagement and Support to Increase Care Plan #Adherence through gamification, social support features and user-friendly interfaces 5️⃣ Data-Driven Insights to Power More Informed Decision-Making and Better Population Health #Management 6️⃣ More robust #Education and #Empowerment through Choice and #HealthLiteracy Digital therapeutics offer a promising pathway to making #healthcare fairer and more equitable by enhancing #accessibility, #affordability, #personalization, #engagement, #data utilization, and patient #empowerment. In a rapidly changing #health environment, leveraging the power of #digital therapeutics can become the great equalizer in addressing systemic disparities and ensuring that all #patients receive the #quality #care they deserve. Hope to see many of you in #Boston in September, ping me if you're in town. PalmHealthCo🌴 #digitalhealth #biopharma #marketacceess #commercialization #managementconsulting #executiveadvisory

Hera Biotech introduces a groundbreaking, less invasive diagnostic approach for endometriosis, transforming patient experiences from years of uncertainty to minutes of clarity. Traditionally, diagnosing endometriosis can take up to eight years, involving invasive procedures and often a long journey of misdiagnosis and pain for millions of women worldwide. Hera Biotech's new technology promises a swift and less invasive method, providing accurate results in minutes, not years. This innovation not only enhances diagnostic precision but also significantly reduces the emotional and physical toll on patients. Read the full article here: https://lnkd.in/gNVVUfYr #Biotech #HealthcareInnovation #Endometriosis #WomensHealth #MedicalTechnology #HeraBiotech #Newzchain

BIG NEWS for #Wisconsin! "The Wisconsin Biohealth Tech Hub, led by BioForward, Inc. Wisconsin, achieves a significant milestone as a Phase 2 recipient of the @U.S. Department of Commerce’s U.S. Economic Development Administration (EDA) Regional Technology and Innovations Hub (Tech Hub) program, affirming Wisconsin’s leadership in #biohealth #technology and #personalizedmedicine. Following a rigorous selection process, the EDA has awarded the Wisconsin Biohealth Tech Hub with $49 million in federal grants to support transformative projects aligned with the program’s overarching goal. Alongside this, an additional $7.5 million in state funding and $24 million in #industry commitments have been secured, bringing the total funding and commitments to over $80 million. This substantial investment will fuel projects to advance personalized medicine, enhance #healthcare outcomes, and drive economic development across Wisconsin. 'We are thrilled to receive a Phase 2 award for the Wisconsin Biohealth Tech Hub,” said Wendy Harris, Regional Innovation Officer. 'This #funding will enable us to accelerate the development and deployment of cutting-edge biohealth solutions, positioning Wisconsin as a global leader in personalized medicine.' Building on the momentum of Phase 1 designation, the Wisconsin Biohealth Tech Hub is poised to expand its impact and drive #innovation in key areas such as imaging/theranostics, #genomics, and big data/analytics. Leveraging strategic partnerships and collaborative efforts, the Tech Hub will focus on initiatives to enhance manufacturing coordination, advance critical genomic technology, and foster talent development in the biohealth sector." The University of Wisconsin-Madison serves as a key partner in the Tech Hub effort. “Collaboration has been key to success for the Wisconsin Biohealth Tech Hub. This unique and multi-disciplinary collaboration is unprecedented, and all consortium members are working together in the best interests of Wisconsin and the world.” - Kurt J. Zimmerman, senior director, Office of Biohealth Industry Partnerships, UW SMPH Press Release: 'Wisconsin Biohealth Tech Hub secures Phase 2 award, catalyzing innovation and economic growth' https://lnkd.in/g9MTEAxg via BioForward #biotech #leadership #OnWisconsin